Published in Eur J Radiol on February 20, 2010
FDG PET in the early diagnosis of large-vessel vasculitis. Eur J Nucl Med Mol Imaging (2013) 1.53
Image guided biodistribution and pharmacokinetic studies of theranostics. Theranostics (2012) 1.14
The use of (18)F-FDG-PET/CT for diagnosis and treatment monitoring of inflammatory and infectious diseases. Clin Dev Immunol (2013) 1.13
FDG-PET/CT in infections: the imaging method of choice? Eur J Nucl Med Mol Imaging (2010) 1.03
The role of 18F-FDG PET/CT in large-vessel vasculitis: appropriateness of current classification criteria? Biomed Res Int (2014) 1.01
The prognostic value of baseline (18)F-FDG PET/CT in steroid-naïve large-vessel vasculitis: introduction of volume-based parameters. Eur J Nucl Med Mol Imaging (2015) 0.92
18F-Fludeoxyglucose PET/CT in the evaluation of large-vessel vasculitis: diagnostic performance and correlation with clinical and laboratory parameters. Br J Radiol (2011) 0.90
A Rationale for the Use of F18-FDG PET/CT in Fever and Inflammation of Unknown Origin. Int J Mol Imaging (2012) 0.88
Imaging large vessel vasculitis with fully integrated PET/MRI: a pilot study. Eur J Nucl Med Mol Imaging (2015) 0.84
Positron emission tomography scanning in anti-neutrophil cytoplasmic antibodies-associated vasculitis. Medicine (Baltimore) (2015) 0.82
Large vessel vasculitis in elderly patients: early diagnosis and steroid-response evaluation with FDG-PET/CT and contrast-enhanced CT. Rheumatol Int (2014) 0.82
Parameters related to a positive test result for FDG PET(/CT) for large vessel vasculitis: a multicenter retrospective study. Clin Rheumatol (2012) 0.81
Place of (18)F-FDG-PET with computed tomography in the diagnostic algorithm of patients with fever of unknown origin. Eur J Clin Microbiol Infect Dis (2012) 0.80
Diagnostic accuracy of 18F-FDG PET or PET/CT for large vessel vasculitis : A meta-analysis. Z Rheumatol (2016) 0.80
Cross-sectional imaging of aortic infections. Insights Imaging (2016) 0.75
Role of (18)F-FDG PET Scan in Rheumatoid Lung Nodule: Case Report and Review of the Literature. Case Rep Rheumatol (2013) 0.75
Fludeoxyglucose positron emission tomography-computed tomography scan showing polyarthritis in a patient with an atypical presentation of Henoch-Schönlein vasculitis without clinical signs of arthritis: a case report. J Med Case Rep (2016) 0.75
Aortic ¹⁸F-FDG uptake in patients suffering from granulomatosis with polyangiitis. Eur J Nucl Med Mol Imaging (2015) 0.75
Diagnostic Value of Positron Emission Tomography Combined with Computed Tomography for Evaluating Critically Ill Neurological Patients. Front Neurol (2017) 0.75
(18)F-FDG PET/CT for diagnosis and treatment response evaluation in large vessel vasculitis. Eur J Nucl Med Mol Imaging (2013) 0.75
The value of FDG-PET in the diagnosis of thromboangiitis obliterans--a case series. Clin Rheumatol (2014) 0.75
Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging (2007) 2.35
Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl Med (2008) 2.27
Calculation of electron dose to target cells in a complex environment by Monte Carlo code "CELLDOSE". Eur J Nucl Med Mol Imaging (2008) 1.97
Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? Eur J Nucl Med Mol Imaging (2010) 1.85
Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy. Eur J Nucl Med Mol Imaging (2007) 1.81
Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology. Nucl Med Commun (2007) 1.72
Preoperative localization and radioguided parathyroid surgery. J Nucl Med (2003) 1.68
Use of [11C]choline PET-CT as a noninvasive method for detecting pelvic lymph node status from prostate cancer and relationship with choline kinase expression. Clin Cancer Res (2011) 1.64
Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study. Eur J Nucl Med Mol Imaging (2011) 1.53
18F-FDG PET/CT impact on testicular tumours clinical management. Eur J Nucl Med Mol Imaging (2013) 1.49
Assessment of response to treatment of unresectable liver tumours with 90Y microspheres: value of FDG PET versus computed tomography. Nucl Med Commun (2007) 1.46
(11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy. Eur J Nucl Med Mol Imaging (2012) 1.44
Role of 99mTc-sestamibi SPECT in accurate selection of primary hyperparathyroid patients for minimally invasive radio-guided surgery. Eur J Nucl Med Mol Imaging (2006) 1.43
Recombinant human TSH in differentiated thyroid cancer: a nuclear medicine perspective. Eur J Nucl Med Mol Imaging (2008) 1.42
Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. Cancer Res (2005) 1.42
Sentinel lymph node biopsy in differentiated thyroid cancer: standard of care or experimental tool? Nucl Med Commun (2006) 1.41
Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis. Clin Nucl Med (2013) 1.34
EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging (2012) 1.28
Papillary thyroid carcinoma: factors influencing recurrence and survival. Ann Surg Oncol (2008) 1.24
2009 EANM parathyroid guidelines. Eur J Nucl Med Mol Imaging (2009) 1.24
Natural history, diagnosis, treatment and outcome of papillary thyroid microcarcinoma (PTMC): a mono-institutional 12-year experience. Nucl Med Commun (2004) 1.21
FDG-PET/CT and parathyroid carcinoma: Review of literature and illustrative case series. World J Clin Oncol (2011) 1.19
Retro-orbital injection is an effective route for radiopharmaceutical administration in mice during small-animal PET studies. Nucl Med Commun (2007) 1.19
Modern nuclear imaging for paragangliomas: beyond SPECT. J Nucl Med (2012) 1.17
Aggressive papillary thyroid microcarcinoma: prognostic factors and therapeutic strategy. Clin Nucl Med (2013) 1.16
68Ga-DOTA-TATE PET vs. 123I-MIBG in identifying malignant neural crest tumours. Mol Imaging Biol (2011) 1.14
Microbial targeting of 99mTc-labeled recombinant human beta-defensin-3 in an animal model of infection: a feasibility pilot study. J Nucl Med (2009) 1.13
The added value of multislice SPECT/CT in patients with equivocal bony metastasis from carcinoma of the prostate. Eur J Nucl Med Mol Imaging (2009) 1.12
A diagnostic approach to mediastinal abnormalities. Radiographics (2007) 1.12
Early monitoring of response to neoadjuvant chemotherapy in breast cancer with 18F-FDG PET/CT: defining a clinical aim. Eur J Nucl Med Mol Imaging (2011) 1.11
11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma. World J Surg Oncol (2007) 1.09
68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. Nucl Med Commun (2009) 1.09
What can gallium-68 PET add to receptor and molecular imaging? Eur J Nucl Med Mol Imaging (2007) 1.06
Radionuclide gastroesophageal motor studies. J Nucl Med (2004) 1.06
Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation. Nucl Med Commun (2005) 1.06
Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med (2007) 1.05
PET/CT imaging in different types of lung cancer: an overview. Eur J Radiol (2011) 1.04
The sentinel node procedure in breast cancer: nuclear medicine as the starting point. J Nucl Med (2011) 1.03
Management and prevention of adverse effects related to treatment of liver tumours with 90Y microspheres. Nucl Med Commun (2007) 1.03
Choline PET/CT for prostate cancer: main clinical applications. Eur J Radiol (2010) 1.02
Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. Eur J Nucl Med Mol Imaging (2007) 1.01
Confirmatory tests in the diagnosis of brain death: comparison between SPECT and contrast angiography. Crit Care Med (2005) 1.01
Parathyroid scintigraphy: when, how, and why? A concise systematic review. Clin Nucl Med (2012) 1.01
Role of 18F-FDG-PET and PET/CT imaging in thyroid cancer. Biomed Pharmacother (2006) 1.01
Development and external validation of a predictive model for pathological complete response of rectal cancer patients including sequential PET-CT imaging. Radiother Oncol (2010) 1.01
Long-term prognostic value of 18F-FDG PET in patients with locally advanced rectal cancer previously treated with neoadjuvant radiochemotherapy. AJR Am J Roentgenol (2006) 1.00
[18F]-3'Deoxy-3'-fluorothymidine positron emission tomography and breast cancer response to docetaxel. Clin Cancer Res (2011) 1.00
Should FDG PET/CT be used for the initial staging of breast cancer? Eur J Nucl Med Mol Imaging (2009) 1.00
Imaging of liver cancer. World J Gastroenterol (2009) 0.99
Increased serum thyroglobulin levels and negative imaging in thyroid cancer patients: are there sources of benign secretion? A speculative short review. Nucl Med Commun (2010) 0.99
Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging (2008) 0.99
Altered tissue 3'-deoxy-3'-[18F]fluorothymidine pharmacokinetics in human breast cancer following capecitabine treatment detected by positron emission tomography. Clin Cancer Res (2009) 0.98
Role of ¹⁸F-choline PET/CT in suspicion of relapse following definitive radiotherapy for prostate cancer. Eur J Nucl Med Mol Imaging (2013) 0.98
Restaging after neoadjuvant chemoradiotherapy for rectal adenocarcinoma: role of F18-FDG PET. Biomed Pharmacother (2004) 0.98
18F-FDG PET in malignant lymphoma: significance of positive findings. Eur J Nucl Med Mol Imaging (2005) 0.98
68Ga DOTATATE PET/CT uptake in spinal lesions and MRI correlation on a patient with neuroendocrine tumor: potential pitfalls. Clin Nucl Med (2013) 0.97
Radionuclide evaluation of the lower gastrointestinal tract. J Nucl Med (2008) 0.97
Anatomical and functional localization of ectopic parathyroid adenomas: 6-year institutional experience. Nucl Med Commun (2011) 0.97
Highlights of the EANM Congress 2011: Birmingham, UK. Eur J Nucl Med Mol Imaging (2012) 0.96
Papillary thyroid carcinoma: 35-year outcome and prognostic factors in 1858 patients. Clin Nucl Med (2007) 0.96
68Ga-citrate PET/CT for evaluating patients with infections of the bone: preliminary results. J Nucl Med (2010) 0.96
68Ga-DOTATATE PET in neuroectodermal tumours: first experience. Nucl Med Commun (2007) 0.96
Radioiodine treatment of hyperthyroidism: fixed or calculated doses; intelligent design or science? Eur J Nucl Med Mol Imaging (2007) 0.95
Role of 18F-choline PET/CT in biochemically relapsed prostate cancer after radical prostatectomy: correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution. Clin Nucl Med (2013) 0.95
Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET. Biomed Pharmacother (2008) 0.95
18F-ICMT-11, a caspase-3-specific PET tracer for apoptosis: biodistribution and radiation dosimetry. J Nucl Med (2013) 0.95
The value of 18F-FDG PET/CT after autologous stem cell transplantation (ASCT) in patients affected by multiple myeloma (MM): experience with 77 patients. Clin Nucl Med (2013) 0.94
68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT. Clin Nucl Med (2016) 0.94
Features of papillary thyroid carcinoma in patients older than 75 years. Updates Surg (2011) 0.94
Assessment of a chemically induced model of lung squamous cell carcinoma in mice by 18F-FDG small-animal PET. Nucl Med Commun (2007) 0.94
Nuclear medicine procedures in the diagnosis and therapy of medullary thyroid carcinoma. Biomed Pharmacother (2007) 0.94
Multislice SPECT/CT in benign and malignant bone disease: when the ordinary turns into the extraordinary. Semin Nucl Med (2009) 0.93
Molecular imaging of pulmonary nodules. AJR Am J Roentgenol (2014) 0.93
Cushing's syndrome caused by an occult source: difficulties in diagnosis and management. Nat Clin Pract Endocrinol Metab (2006) 0.92